Although redundancy and plasticity of cytokine responses potentially account for the lack of efficacy observed following anti-IL-17 or anti-IFN-γ monotherapy, it is now appreciated that IBD is heterogeneous in terms of clinical phenotype, mucosal immune response, and genetic risk. The gene discussed is IL17A; the disease is inflammatory bowel disease.